

## **PRESCRIBER SAFETY** Initiative

The federal government has prioritized increasing the number of health care practitioners who treat opioid use disorder (OUD) using medications approved by the Food and Drug Administration.<sup>1</sup>

Practitioners authorized to prescribe buprenorphine for OUD have cited the following reasons, among others, for their reluctance to prescribe the medication:

- Inadequate training;
- Burdensome regulatory requirements; and
- Increasing regulatory and law enforcement scrutiny.<sup>2</sup>

### **The Prescriber Safety Initiative responds to these concerns.**

We equip practitioners to feel confident treating patients with OUD and other medical conditions that may require controlled medications.

Contact us at [info@prescribersafety.org](mailto:info@prescribersafety.org):

<sup>1</sup> OFFICE OF NATIONAL DRUG CONTROL POLICY, NATIONAL DRUG CONTROL STRATEGY, 8-13, (2019).

<sup>2</sup> Sonia Mendoza, et. al. Shifting Blame: Buprenorphine Prescribers, Addiction Treatment, and Prescription Monitoring in Middle-class America, NATIONAL INSTITUTES OF HEALTH, U.S. NATIONAL LIBRARY OF MEDICINE (Aug. 3, 2016) <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5540139/>

## **PRESCRIBER SAFETY** Initiative

Drawing from our legal and regulatory experience, we provide up-to-the-minute, practical tips on the following topics, among others:

- Controlled Substances Act, Drug Addiction Treatment Act of 2000, and state-law compliance and recordkeeping;
- Health care fraud prevention;
  - Medicaid and Medicare ordering, prescribing, and referring;
  - Urine drug testing methodology, frequency, analyte selection, and clinical response; and
- Drug diversion, patient discharge, abandonment claims, privacy, and other risk management issues.

**We help professionals be safe and feel safe while prescribing controlled medications.**

Contact us at [info@prescribersafety.org](mailto:info@prescribersafety.org).